



*Working to improve your health*

3 June 2024

## **AFT to launch Maxigesic® Rapid in the United States.**

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an agreement with Alexso to distribute Combogesic® (Maxigesic Rapid Tablets) in the United States, the largest pharma market in the world<sup>1</sup>.

AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: "We are delighted to announce our partnership with Alexso, an established pharmaceutical distribution company which prioritizes non-opioid pain management solutions.

We are pleased to be launching our second patented pharmaceutical into the United States market, which we anticipate will occur during this financial year."

"Troy Farahmand, President of Alexso, stated: 'We are thrilled to introduce Combogesic to our portfolio of non-opioid pain management solutions. This partnership with AFT Pharmaceuticals aligns perfectly with our commitment to offering physicians effective alternatives to opioids. Combogesic will play a crucial role in our mission to combat pain while reducing the reliance on addictive opioid medications.'".

AFT's negotiations continue to progress with other distributors for additional specific market channels in the United States.

*For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.*

### **For more information:**

#### **Investors**

Dr Hartley Atkinson  
Managing Director  
AFT Pharmaceuticals  
Tel: +64 9488 0232

#### **Media**

Richard Inder  
The Project  
Tel: +64 21 645 643

#### **Footnote**

1. <https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/>

### **About AFT Pharmaceuticals**

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs<sup>1</sup>. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website [www.aftpharm.com](http://www.aftpharm.com).

### **About Alexso**

At Alexso, Inc., our mission is to be a leading pharmaceutical wholesale distribution company that prioritizes non-opioid pain management solutions. Through our unwavering commitment to excellence, we aim to provide healthcare professionals with a diverse range of specialized products and services, catering to unique marketing niches. By fostering innovation, promoting patient well-being, and building strong partnerships, we strive to positively impact communities and advance the field of pain management, ultimately improving lives and ensuring a healthier tomorrow.